RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL Studio lets pharmacokinetic (PK) and pharmacodynamic (PD) scientists create these components with greater speed and collaboration.
Traditional TFL workflows are often hindered by manual processes, fragmented tools, and the challenges of maintaining visual quality and consistency across studies. Phoenix Cloud is designed to accelerate these and related PK workflows through AI and cloud technology.
"The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development," said William F. Feehery, Chief Executive Officer.
A complementary module, AI PK Reports, will be released this quarter. AI PK Reports leverages GenAI to turn tables, figures, and listings into draft PK reports, reducing a process that typically takes scientists days to complete down to minutes. AI PK Reports are powered by CoAuthor™, Certara’s GenAI software for regulatory and medical writing.
TFL Studio delivers a user-friendly, no-code environment where scientists can:
"TFL Studio empowers scientists to create high-quality TFLs up to 50% faster, freeing them from the technical complexities of moving source data, coding, and manual formatting,” said Martin Snyder, President, Certara Data Sciences. “This allows them to focus on science, derive insights more quickly, and ultimately accelerate critical decision-making."
As the inaugural cloud-native module of Phoenix Cloud, TFL Studio sets the stage for future innovations, including the AI PK Reports module described above. It integrates with Integral™, Certara’s data repository, providing a single source of truth for PK/PD data, models and visualizations.
TFL Studio is available now as part of the Phoenix Cloud solution. To learn more about TFL Studio and the Phoenix Cloud platform, visit https://www.certara.com/software/phoenix-pkpd/phoenix-cloud/.
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com
Certara contact:
Sheila Rocchio
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$8.67 |
| Daily Change: | -2.60 -23.07 |
| Daily Volume: | 10,666,779 |
| Market Cap: | US$1.390B |
November 06, 2025 October 30, 2025 September 04, 2025 August 06, 2025 August 04, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load